Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
09:03am, Wednesday, 17'th Jul 2024
Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for its ex
Roche shares jump on drugmaker's early-stage data on weight-loss drug
08:45am, Wednesday, 17'th Jul 2024
Shares of Swiss drugmaker Roche rallied on Wednesday after the company's early-stage trial of an oral weight-loss drug showed it had promise.
Roche Climbs As Once-Daily Weight Loss Pill Shows Promise
07:10am, Wednesday, 17'th Jul 2024
Shares of Swiss pharma giant Roche climbed Wednesday after it reported promising results for an experimental weight loss pill, part of a cohort of hopeful competitors racing to challenge Novo Nordisk
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche
06:19am, Wednesday, 17'th Jul 2024
Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate. Roche said its experimental once-daily pill showed average weight loss
Roche reports positive early results in CT-966 obesity drug trial
01:51am, Wednesday, 17'th Jul 2024
Roche said on Wednesday that its CT-996, a GLP-1 receptor agonist to treat obesity and type 2 diabetes, has had positive results in phase one of its clinical trial.
Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity
01:10am, Wednesday, 17'th Jul 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from two arms of an ongoing multi-part Phase
Basel, 17 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-dai
Roche Holding's (RHHBY) Accu-Chek SmartGuide Receives CE Mark
01:11pm, Friday, 12'th Jul 2024
Roche Holding (RHHBY) announces the receipt of CE Mark for its Accu-Chek SmartGuide CGM solution which is intended toward providing better diabetes management.
Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration
07:00am, Wednesday, 10'th Jul 2024
The collaboration leverages Remix's REMaster™ platform to discover novel drugs for a diverse range of target classes Remix is eligible to receive up to $1 billion in milestone payments and royalt
In France, political paralysis is economic paralysis: David Roche
07:54am, Tuesday, 09'th Jul 2024
David Roche, strategist at Quantum Strategy, discusses the economic implications of the latest political developments in France.
Basel, 09 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received the CE Mark for its Accu-Chek SmartGuide® continuous glucose monitoring (CGM) solution. This significant
Roche reintroduces recalled eye implant in US
12:10pm, Monday, 08'th Jul 2024
Genentech, a unit of Roche Group , said on Monday it has reintroduced its ocular implant, Susvimo, in the United States, following the end of a voluntary recall.
Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)
11:45am, Monday, 08'th Jul 2024
Basel, 08 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of
Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe
10:01am, Friday, 05'th Jul 2024
The FDA approves Roche's (RHHBY) Vabysmo prefilled syringe for treating three retinal conditions that can cause blindness.
Keir Starmer does not have the tools or vision to turn the UK economy around: David Roche
03:15am, Friday, 05'th Jul 2024
David Roche of Quantum Strategy says he expects the markets to respond positively to a victory for the Labour Party's Keir Starmer, but this does not change the declining trajectory of the UK economy.
